The U.S. Food and Drug Administration (FDA) has approved a new formulation of the anticancer therapy nilotinib, branded Cavhanza, to treat certain people with chronic…
News
PANCREATIC CANCER
Collaboration to test 2 pancreatic cancer treatments in combination
Ideaya Biosciences and Roche announced a collaboration to test two experimental treatments for pancreatic cancer in combination. The companies will test Ideaya’s…
Add-on treatment with DeltEx DRI, a cell therapy being developed by In8bio, may help prolong survival in people with glioblastoma, an aggressive form of…
GYNECOLOGICAL CANCER
Immunotherapy duo shows promise in tough gynecological cancers
A combination of the immune-modulating treatments Lymphir (denileukin diftitox) and Keytruda (pembrolizumab) led to clinical benefit in nearly half of evaluable patients in an exploratory clinical…
Treatment with a regimen based on the experimental therapy mezigdomide reduced the risk of disease progression or death by more than 50% compared with standard…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to STX-0712, an experimental therapy Solu Therapeutics is developing to treat chronic myelomonocytic…
PANCREATIC CANCER
New chemotherapy delivery method scores FDA orphan drug status
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental delivery method for the chemotherapy oxaliplatin as a potential treatment…
An experimental therapy designed to mimic vitamin B12 and deliver a toxic molecule to tumor cells showed promise as a potential treatment for an aggressive…
GYNECOLOGICAL CANCER
Vaccine plus Keytruda bests standard care for hard-to-treat ovarian cancer
The experimental cancer vaccine Tedopi (OSE2101), when given in combination with the approved injection therapy Keytruda (pembrolizumab), outperforms standard-of-care treatment in delaying disease…
For World Blood Cancer Day this May 28 — a day when advocates around the globe join forces to raise awareness…
Recent Posts
- The caregiver’s invisible ledger tracks what no one else sees
- Study shows protein marker helps predict aggressive myeloma
- New combination therapy cuts risk of death in hard-to-treat myeloma
- Early AML trial finds experimental therapy was generally well tolerated
- Stopping myeloma maintenance therapy at 2 years is safe, study shows
